<DOC>
	<DOC>NCT01579500</DOC>
	<brief_summary>The purpose of this study is to determine whether botulinum toxin A is effective in the treatment of neuropathic pain in spinal cord injury patients.</brief_summary>
	<brief_title>Neuropathic Pain Study With Botulinum Toxin A in Spinal Cord Injury Patients</brief_title>
	<detailed_description>Neuropathic pain remains a significant cause of life quality deterioration. This study includes spinal cord injury patients with refractory chronic neuropathic pain and investigates whether injection with botulinum toxin A improves pain scores.</detailed_description>
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Spinal Cord Injuries</mesh_term>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Botulinum Toxins, Type A</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins</mesh_term>
	<criteria>more than twenty years of age paraplegic or tetraplegic due to cervical and thoracic spinal cord injury more than 12 months since spinal cord injury and ASIA impairment scale unchanged for more than 6 months persistence of neuropathic pain for more than three months or remission and recurrence of neuropathic pain for more than six months a pain score of 40mm or more on the visual analogue scale neuropathic pain caused by confounding factors other than spinal cord injury contraindicated for botulinum toxin type A a change in pain medication one month prior to study enrollment a condition involving neuromuscular junction (Ex. Eaton Lambert disease, myasthenia gravis) person who received botulinum toxin type A within three months prior to study enrollment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>